Understanding how epigenetics affects pancreatic cancer subtypes
Exploring the epigenetic control of pancreatic cancer subtypes
['FUNDING_R37'] · FRED HUTCHINSON CANCER CENTER · NIH-10796686
This study is looking at how certain changes in genes might affect the behavior of a tough type of pancreatic cancer, with the goal of finding new ways to treat it better, especially for patients with the aggressive form of the disease.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10796686 on ClinicalTrials.gov |
What this research studies
This research investigates the role of epigenetic mechanisms in determining the characteristics of pancreatic ductal adenocarcinoma (PDA), particularly focusing on the aggressive quasi-mesenchymal subtype. By analyzing how certain epigenetic regulators influence tumor behavior, the study aims to identify new therapeutic targets that could improve treatment outcomes. The approach includes examining the effects of a specific histone deacetylase, SIRT6, which has shown promise as a tumor suppressor in preliminary models. Patients may benefit from insights that could lead to more effective therapies tailored to their specific cancer subtype.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with the quasi-mesenchymal subtype.
Not a fit: Patients with other types of pancreatic cancer or those whose disease is not classified as quasi-mesenchymal may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that significantly improve survival rates for patients with aggressive pancreatic cancer.
How similar studies have performed: Other research has shown promise in targeting epigenetic mechanisms in cancer, suggesting that this approach could yield significant advancements in treatment.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KUGEL, SITA — FRED HUTCHINSON CANCER CENTER
- Study coordinator: KUGEL, SITA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Cause, Cancer Etiology, Cancer Suppressor Genes, Cancers